Symbols

BTMD

biote·NASDAQ

--(--)

BTMD fundamentals

BTMD Q4 2025 Earnings

biote (BTMD) released its earnings on Mar 11, 2026: revenue was 46.41M (YoY -6.87%), beat estimates; EPS was 0.06 (YoY -40.00%), beat estimates.

Revenue / YoY

46.41M

-6.87%

EPS / YoY

0.06

-40.00%

Report date

Mar 11, 2026

BTMD Earnings Call Summary for Q4,2025

2026 Growth Catalysts: $10M+ investment in salesforce expansion to 120 and tech platform to drive H2 procedure revenue growth.
Recall Impact: Q4 2025 gross margin hit by $1.3M charge, but Asteria vertical integration expected to improve margins in 2026.
FDA Regulatory Tailwind: Removal of HRT black box warnings and FDA collaboration on recall position Biote as a leader in safe, science-based solutions.
EBITDA Outlook: 2026 EBITDA >$38M (+8% YoY) despite near-term costs, reflecting disciplined investment in long-term growth.

Earnings

EPS

Revenue

Revenue & Expenses

BTMD has released its 2025 Q4 earnings report, with revenue of 46.41M, reflecting a YoY change of -6.87%, and net profit of 2.62M, showing a YoY change of -24.86%. The Sankey diagram below clearly presents BTMD's revenue sources and cost distribution.

Key Indicators

biote (BTMD) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

biote (BTMD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

biote (BTMD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

biote (BTMD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown